EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives

Ahmed Noor Eddin iD, Mohammed Alfuwais, Reena Noor Eddin, Khaled Alkattan iD, Ahmed Yaqinuddin iD

Nutrients · 21.02.2024 · 16 (5) · 590

DOI: 10.3390/nu16050590 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 21.02.2024. Verfasst von Ahmed Noor Eddin und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Gastrointestinal Microbiome, Microbiota. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut–brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisGastrointestinal MicrobiomeMicrobiotaAnimalsHumansDysbiosisDisease Progression

Stichwörter der Autor:innen

amyotrophic lateral sclerosisdysbiosisgut modulationgut-brain axismicrobiotaneurodegenerationprobioticstherapeutics

Autor:innen und Institutionen

  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.

ORCID-Profile: Ahmed Noor Eddin, Khaled Alkattan, Ahmed Yaqinuddin

Zitieren

APA

Noor Eddin, A., Alfuwais, M., Noor Eddin, R., Alkattan, K., & Yaqinuddin, A. (2024). Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients, 16(5), 590. https://doi.org/10.3390/nu16050590

Vancouver

Noor Eddin A, Alfuwais M, Noor Eddin R, Alkattan K, Yaqinuddin A. Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients. 2024;16(5):590. doi:10.3390/nu16050590

BibTeX
@article{NoorEddin2024,
  author = {Noor Eddin, Ahmed and Alfuwais, Mohammed and Noor Eddin, Reena and Alkattan, Khaled and Yaqinuddin, Ahmed},
  title = {Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {590},
  doi = {10.3390/nu16050590}
}
Kostenlos starten →